Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACP-103 · 2 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| ACP-103 | DRUG | - |
Inclusion Criteria: * male or female subjects ages 18-65 diagnosed with schizophrenia * experiencing an acute exacerbation of psychosis * has had prior response to antipsychotic therapy within the previous 3 years * female subjects must be of non-childbearing potential or must comply with double-ba...
ACP-103 is an investigational small molecule being studied for schizophrenia and hallucinations. It has been evaluated in Phase 2 clinical trials for these neurological conditions, including in patients with Parkinson's disease who experience hallucinations or psychosis.
ACP-103 is being developed by ACADIA Pharmaceuticals Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ACAD. The company is conducting clinical research to evaluate the drug's potential in treating schizophrenia and hallucinations.
ACP-103 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy for treating schizophrenia and hallucinations.
ACP-103 has been studied in two completed Phase 2 clinical trials. NCT00087542 evaluated the drug for hallucinations and psychosis in Parkinson's disease with 60 participants in the United States. NCT00361166 assessed its antipsychotic and motor effects when combined with haloperidol and risperidone in 400 participants with schizophrenia across the United States and Brazil.
ACP-103 is also known by the name pimavanserin. It is being developed by ACADIA Pharmaceuticals for the treatment of schizophrenia and hallucinations, including hallucinations associated with Parkinson's disease.